跳到正文
Pharmaceutical Commerce·· 3 天前AI 评分35

Pharma Pulse:FDA启动全球依赖披露计划(GRDP)

Pharma Pulse: FDA Launches Global Reliance Program

AI 导读

FDA宣布启动全球依赖披露计划(GRDP),可向企业分享经最低限度脱敏的审评资料包,供其转交美国境外监管机构参考。该计划随lenacapavir的暂定批准一同推出,目前仅覆盖PEPFAR下的暂定批准,2027年1月起拟扩展至全部新药申请和生物制品许可申请。

正文 · 原文

In this week’s Pharma Pulse, the FDA launches a program that lets companies share its approval packages with foreign regulators, UPS agrees to acquire Australia and New Zealand health care courier Smartways Logistics and Cognizant introduces an AI-enabled patient hub offering.

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast bringing you the latest insights shaping supply chain, market access and regulatory policy. I’m your host, and let’s get into this week’s headlines.

First up, the FDA wants its drug reviews to travel further. The agency announced the Global Reliance Disclosure Program, or GRDP, which lets it share minimally redacted approval packages, including its scientific and regulatory assessments, with companies that can pass them to regulators outside the United States.1 Those regulators can then rely on the FDA’s review instead of conducting a duplicative evaluation of their own, while keeping authority over their own decisions.

The program launched alongside a tentative approval for lenacapavir, which is indicated for HIV prevention and treatment. For now, it only covers tentative approvals under the President's Emergency Plan for AIDS Relief, excluding tentatively approved generics. That changes in January 2027, when the FDA intends to open the GRDP to all new drug applications and biologics license applications. The agency also plans an early 2027 pathway to expedite requests for packages on drugs and biologics already approved or licensed in the US.

According to the FDA, patients in many parts of the world may wait months or years longer for their national regulator to finish an independent review because of limited capacity and resources. This program is intended to shorten that timeline.1

Next, UPS is set to add a dedicated health care courier network in Australia and New Zealand. The company agreed to acquire Smartways Logistics, a health care logistics provider serving Australia and New Zealand, in a deal it says will enhance UPS Healthcare’s time-critical transportation capabilities in the region.2 Financial terms weren’t disclosed, and the deal is expected to close in the first half of 2027, subject to regulatory reviews and approvals.

Smartways offers next-flight-out, same-day ground and overnight transportation, along with reverse logistics and 3PL solutions, for clients that include medical device, pharmaceutical, clinical trial and radiopharmaceutical companies. Smartways says its more than 350 drivers form the region’s largest dedicated health care network. UPS framed the acquisition as part of its continued health care investment in Asia Pacific, pointing to its recently opened Clark hub in the Philippines and its cold chain investments.

Lastly, Cognizant is putting AI agents to work on the steps between a prescription and the start of therapy. The company introduced Cognizant Patient Hub Operations, an offering built on NVIDIA accelerated computing that pairs AI agents with experienced specialists.3 Instead of handling coverage confirmation, insurer authorization and financial assistance one after another, the offering starts all three at intake so cases move in parallel. Cognizant says it aims to cut the typical time from prescription to therapy from about 30 days to less than seven, a target based on its own analysis of current patient access workflows and case volumes.

AI agents handle patient conversations and routine administrative work using each program’s prescribing information, standard operating procedures and payer rules. Cognizant specialists review, approve or escalate AI-prepared actions and keep the final say on any decision governed by regulations. At launch, the offering includes five agents covering patient inquiry, intelligent routing, translation, human handoff and call summarization.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access, visit pharmaceuticalcommerce.com. Thanks for listening, until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.

References

  1. US Food and Drug Administration. “FDA Launches the Global Reliance Disclosure Program to Expand Patient Access to Medicines Worldwide.” November 17, 2026. Accessed November 19, 2026. https://www.fda.gov/news-events/press-announcements/fda-launches-global-reliance-disclosure-program-expand-patient-access-medicines-worldwide
  2. Appezzato S. “UPS to Acquire Smartways Logistics, Expanding APAC Health Care Reach.” Pharmaceutical Commerce. November 18, 2026. Accessed November 19, 2026. https://www.pharmaceuticalcommerce.com/view/ups-to-acquire-smartways-logistics-expanding-apac-healthcare-reach
  3. Cognizant. “Introducing Cognizant Patient Hub Operations: AI-enabled patient access offering designed to shorten the path from prescription to therapy.” PR Newswire. November 18, 2026. Accessed November 19, 2026. https://www.prnewswire.com/news-releases/introducing-cognizant-patient-hub-operations-ai-enabled-patient-access-offering-designed-to-shorten-the-path-from-prescription-to-therapy-302943864.html

Related to this article

Konskie, Poland - March 27, 2025: Hims and Hers Health company logo displayed on mobile phone | © piter2121 - stock.adobe.com 1541484715

November 12th, 2026

In this week’s Pharma Pulse, Lilly brings Zepbound and Foundayo to Hims & Hers, Swisslog Healthcare expands its Tenutō cold storage line, and FDA adds a NAION warning across the GLP-1 class.

Read more

CVS Pharmacy Sign at Storefront Entrance | © Mark Roger Bailey - stock.adobe.com 557616813

November 4th, 2026

In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.

Read more

Sep 2, 2020 Sunnyvale / CA / USA - GoodRx Card placed in front of the GoodRx app open on a smartphone; GoodRx is a startup company providing prescription drugs discounts and a telemedicine platform. | © Sundry Photography - stock.adobe.com 377582664

October 29th, 2026

In this week’s Pharma Pulse, GoodRx expands an employer offering built on manufacturer pricing for GLP-1 obesity drugs, a federal judge declines to block Lilly’s comparative Zepbound ads, and the PBM industry’s trade group turns the vertical integration debate toward drug wholesalers.

Read more

UPS airplane tails at the airport. | © Debra Lawrence - stock.adobe.com 558200881

November 18th, 2026

UPS' deal for Smartways Logistics adds a dedicated health care courier network in Australia and New Zealand to its Asia Pacific buildout.

Read more

The whitehouse in washington dc. | © Gary - stock.adobe.com 2730090

November 18th, 2026

The White House pulled Heidi Overton's FDA nomination a day before a Senate HELP vote, leaving acting Commissioner Kyle Diamantas in charge.

Read more

Abstract digital graphic shows glowing capsule on circuit board. Futuristic pharma tech concept with dna strands and data graphs. Innovation in medicine.  | © Pete - stock.adobe.com 1863459792

November 16th, 2026

Fragmented data is eroding trust in pharma insights, and AI raises the stakes. A four-step approach can help organizations pay down their “data debt.”

Read more

Concept: Trade protectionism by the USA by implementing 100% tariffs on "Pharmaceutical Products". A security fence built around a map of the USA with blisters of pills and signs "Tariffs" and "100%". | © Andreas Prott - stock.adobe.com

November 13th, 2026

Thani Jambulingam, Ph.D., says MFN pricing, Section 232 tariffs and PBM reform will converge to shape how pharma launches and commercializes new drugs.

Read more

Ed Schoonveld is a Value & Access advisor for Schoonveld Advisory, LLC and author of The Price of Global Health

November 9th, 2026

How the midterm results stall Trump’s MFN push, and why differential pricing, compulsory licensing and transparency dominate the WHO Fair Pricing Forum.

Read more

来源:Pharmaceutical Commerce · pharmaceuticalcommerce.com